Buy the Business, Not the Rocket: Why Rocket Lab’s Growth Is Already Real

Hook & thesis

Investors have spent the last two weeks treating Rocket Lab (RKLB) like a single-program binary: Neutron makes or breaks the stock. That mistake is creating an actionable opportunity. The market cap of roughly $40.6 billion already prices a lot of future upside, but the company's immediate revenue engines - high-frequency Electron launches, growing Space Systems work, defense hypersonic test flights, and a $1.85 billion backlog - are tangible, recurring drivers that will materially reduce execution risk long before Neutron matters.

My trade idea: be long a tactical position in RKLB to capture a re-rate as the market refocuses on recurring revenues and margin improvement rather than one delayed heavy-lift program. Entry, stop and targets are listed in the trade plan below. This is a mid-term trade - not a binary long-only punt on Neutron.

What Rocket Lab actually does and why the market should care

Rocket Lab operates two clear segments: Launch Services and Space Systems. Launch Services sells dedicated and rideshare launches using Electron and other operational vehicles. Space Systems is spacecraft engineering, components, manufacturing and on-orbit operations. Beyond commercial satellites, Rocket Lab has meaningful defense exposure through hypersonic test launches and classified payloads. That mix matters because launches are recurring, mission-driven revenue and Space Systems gives recurring engineering and manufacturing contracts with longer tails.

Why this is important now: the company just demonstrated rapid operational tempo and reliability - completing its 83rd launch and multiple launches within a single week - and it recorded record annual sales. Those operational data points feed into revenue growth, backlog conversion and margin expansion, the ingredients for a re-rating independent of Neutron's timeline.

Hard numbers that support the argument

• Record annual sales: $602 million for the year, with Q4 revenue of $179.65 million that beat the $178.47 million consensus. That is recent, real top-line growth rather than projections.
• Backlog: $1.85 billion reported, which gives forward revenue visibility and supports multiple years of revenue conversion even if Neutron is delayed.
• Market capitalization: roughly $40.56 billion at current prices, implying the market is pricing a very large future payload of value into RKLB.
• Liquidity and operating picture: powder-keg revenue growth - the company has been growing rapidly, and operating cadence remains strong (83 launches completed to date, multiple launches in March 2026).
• Valuation metrics show the disconnect: price-to-sales sits around 67.4 and price-to-book near 23.56, signs the market has already priced big future contributions (chiefly Neutron).
• Technicals: short-term indicators are constructive. SMA10 is $70.65 and SMA20 is $70.97 while current price sits around $72.09. RSI is neutral at ~48 and MACD shows bullish momentum developing - a setup for short-covering and momentum-driven rebounds.
• Balance sheet and capital flow: the company reports cash roughly $2.48 billion and an enterprise value near $39.9 billion. Free cash flow was negative recently (-$321.8 million), reflecting heavy investment in capacity and programs.

Valuation framing

At a market cap north of $40 billion and P/S about 67, RKLB trades like a high-conviction growth story where most future profits come from programs still to be realized. That premium is driven by expectations for Neutron to unlock a step-change in TAM and scaled revenue. But the other side of that argument is simple - you do not need Neutron achieving flawless execution this quarter for Rocket Lab to materially improve fundamentals.

If Electron continues at a high cadence and Space Systems converts backlog into multi-quarter revenue, those cash flows address a meaningful portion of the present valuation gap. The current multiples are not 'cheap' by any stretch, and I am not arguing for a deep-value trade. Instead I see a tactical rebound trade that buys time for the business to demonstrate that a large portion of its growth is already visible in backlog and recurring launches.

Catalysts to drive a re-rate

• Continued high cadence of Electron launches and further mission announcements - each successful launch reduces perceived execution risk and drives revenue recognition.
• Backlog conversion: steady quarterly revenue beats and guidance raises as the $1.85 billion backlog ships into revenue.
• Defense wins and repeat business for hypersonic test launches - these are high-margin, high-visibility contracts that increase recurring revenue and margins.
• Integration benefits from the OSI acquisition that improve gross margins and defense exposure, announced on 03/09/2026.
• Short interest dynamics: meaningful reduction in reported short positions (from ~57M earlier to ~21M by 02/13/2026) and continued heavy short-volume can accelerate moves higher on good news.

Trade plan - specific, actionable

Entry: $70.00
Target: $95.00
Stop loss: $64.00
Trade direction: Long
Time horizon: mid term (45 trading days) - plan to hold through a sequence of operational catalysts and potential short-covering. If the position is working, consider extending to a position-holding horizon up to 180 trading days to let backlog conversion and margin improvements play out.

Rationale: entry at $70 puts you slightly below the short-term moving averages (SMA10 $70.65, SMA20 $70.97) to give the trade room to absorb volatility. Stop at $64 is a technical fail point below recent intraday supports and provides defined downside control. Target $95 captures a meaningful portion of upside toward the stock's recent highs ($99.58 52-week high) while recognizing the market requires demonstrable revenue/margin improvements to justify higher multiples.

Position sizing & risk management

This is a medium-risk trade. Given the stock's high valuation and negative recent FCF, keep position size limited to a fraction of liquid equity exposure (for most retail accounts, 1-3% of portfolio). Trail stops upwards if the stock moves rapidly in your favor, and be prepared to trim into strength as the market re-prices growth expectations.

Risks and counterarguments

Primary risks:

• Neutron remains a valuation anchor - continued delays or cost overruns could push the market to mark the company back down despite good performance in other segments.
• Cash burn and negative free cash flow (-$321.8 million recently) mean that operational missteps or unexpected capital needs could force dilution or expensive financing.
• Execution risk on Space Systems scaling - converting backlog into profitable revenue is not guaranteed and could come with higher-than-expected costs.
• Macro/market: a broad risk-off in high-growth tech names or a spike in interest rates could rapidly compress the lofty multiples RKLB currently trades at.
• Concentration of investor expectations - with P/S and P/B at extreme levels, sentiment can swing quickly and violently if anything underwhelms.

Counterarguments

• One could reasonably argue that the valuation already assumes substantial successes across multiple programs and that the path to justify a $40 billion market cap requires flawless execution from Neutron, which is still distant. If Neutron were to fail or be materially delayed further, the rerating could be severe.
• Another counterpoint: negative free cash flow and ongoing capital intensity make the company dependent on investor goodwill or debt markets; in a tightening environment that could be costly.

Why I still prefer a tactical long

Those counterarguments are valid; this is why the trade is sized modestly and bounded with a strict stop. But they do not negate the fact that Rocket Lab already sells launches today, is converting backlog into revenue, and has real defense contracts and repeated hypersonic mission successes that are unlikely to disappear overnight. The company beat Q4 revenue expectations and posted record annual sales, showing the business is executing at scale. If management continues to deliver steady beats while Neutron remains delayed but intact, the market will refocus on earned cash flows rather than discounted promise.

What would change my mind

I would abandon this trade if any of the following occur: a) management reports an acceleration of cash burn without a credible liquidity plan; b) backlog erosion or cancellations that materially reduce forward revenue visibility; c) another major program delay beyond Q4/2026 for Neutron with clear signs of systemic engineering or supplier failures; or d) a sustained technical breakdown below $64 with rising volume pushing price lower, which would indicate market participants are repricing long-term expectations.

Conclusion

Rocket Lab is more than a one-rocket story. The market's fixation on Neutron timing has blurred the value of recurring launch revenue, an expanding Space Systems business, defense mission wins and a sizable backlog. Those are real cash flows that can produce a meaningful re-rating even before Neutron reaches orbit. This trade is a mid-term, risk-defined long that plays for a recovery in sentiment and near-term fundamentals, not a speculative bet that Neutron will succeed unquestioningly. Entry $70, stop $64, target $95 - manage size and tighten the stop if the trade goes your way.

Quick reference

Trade idea summary: tactical long at $70, stop $64, target $95, mid term (45 trading days). Buy the business reopening its path to value rather than speculating only on Neutron.